Ekso Bionics Plunges 19.64% on Revenue Drop

On May 20, 2025, Ekso Bionics experienced a significant drop of 19.64% in pre-market trading, reflecting a notable decline in investor sentiment.

Ekso Bionics recently reported its first-quarter results for 2025, revealing a 10% year-over-year decrease in revenue to $3.37 million. This decline was primarily attributed to lower sales of the EksoNR devices used in rehabilitation centers. However, the company saw an increase in sales of the Ekso Indego Personal device for in-home use, which partially offset the loss. CEO Scott Davis highlighted the expanded access to the Ekso Indego Personal devices, noting that while there was some softness in the legacy enterprise business due to macroeconomic uncertainties, the personal device segment showed good growth.

In response to the financial performance, Ekso Bionics announced a 1-for-15 reverse stock split effective May 27, 2025. This move aims to raise the per-share trading price and help the company regain compliance with Nasdaq's minimum bid price requirement. The reverse split will reduce the number of outstanding shares from 35.3 million to 2.35 million, potentially stabilizing the stock price and improving market perception.